Neon Therapeutics
We turn cancer’s most daunting weapon into its biggest vulnerability.
We turn cancer’s most daunting weapon into its biggest vulnerability.
Neon Therapeutics, a clinical-stage immuno-oncology company, is at the forefront of the neoantigen-targeted therapy field, aiming to revolutionize cancer treatment by harnessing the immune system against neoantigens. Established in 2015 and headquartered in the United States, Neon Therapeutics has garnered significant attention with its $36.00M Series B investment in December 2017. Notable investors in this round include Casdin Capital, Wellington Management, Access Industries, ArrowMark Partners, Fidelity, Nextech Invest, PFM Health Sciences, Hillhouse Investment, and Inbio Ventures. The company's mission of converting cancer's most formidable weapon into its greatest vulnerability is exemplified by its dedication to pioneering new approaches in biotechnology and healthcare. For further details, please visit Neon Therapeutics and follow them on Twitter at @Neon_Tx.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $36.00M | 9 |
|
05 Dec 2017 |
| Series B | $70.00M | 1 |
|
05 Jan 2017 |
| Series A | $55.00M | - | 01 Oct 2015 |
No recent news or press coverage available for Neon Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
